Orly Vardeny

Q: What Schools Are Affiliated With Orly Vardeny

Orly Vardeny is affiliated with the following schools: University of Minnesota, University of Wisconsin–Madison, University of Glasgow, University of Lorraine, Harvard University

Orly Vardeny's AcademicInfluence.com Rankings

Orly Vardeny

Medical

#3355

World Rank

#3823

Historical Rank

Pharmacology

#416

World Rank

#469

Historical Rank

medical Degrees

Download Badge

Medical

Orly Vardeny's Degrees

PhD Pharmacology University of California, San Diego

Why Is Orly Vardeny Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Orly Vardeny's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 (2020) (1664)
Potential Effects of Coronaviruses on the Cardiovascular System: A Review. (2020) (1521)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (2022) (467)
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure (2021) (395)
Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. (2021) (263)
Recognition and Initial Management of Fulminant Myocarditis (2020) (262)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (2022) (250)
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. (2022) (225)
Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). (2012) (213)
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial (2016) (171)
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. (2014) (159)
Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist (2014) (158)
Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19. (2021) (154)
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction (2019) (138)
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial (2017) (130)
Guidelines for the primary prevention of stroke : a guideline for health care professionals from the American Heart Association / American Stroke Association (2013) (121)
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. (2016) (113)
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial (2019) (106)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (2022) (103)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (2022) (90)
Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure: The Atherosclerosis Risk in Communities Study (2019) (87)
Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19 (2020) (84)
Interprofessional Education: Principles and Application A Framework for Clinical Pharmacy (2009) (75)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. (2022) (71)
Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. (2013) (69)
Insulin resistance and incident heart failure the ARIC study (Atherosclerosis Risk in Communities). (2013) (67)
Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study (2015) (65)
Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. (2019) (58)
Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities) (2016) (54)
Clinical Pharmacy Services in Heart Failure: An Opinion Paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network (2013) (49)
Kidney Function and Outcomes in Patients Hospitalized with Heart Failure. (2021) (48)
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. (2022) (47)
The Essential Research Curriculum for Doctor of Pharmacy Degree Programs (2010) (47)
Deprescribing for Community-Dwelling Older Adults: a Systematic Review and Meta-analysis (2020) (44)
Trends in prevalence of comorbidities in heart failure clinical trials (2020) (43)
Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19 (2020) (42)
Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. (2020) (39)
Cardiovascular implications of COVID-19 versus influenza infection: a review (2020) (39)
Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study (2016) (39)
Nutrition and heart failure: impact of drug therapies and management strategies. (2009) (39)
Effects of hydroxychloroquine treatment on QT interval (2020) (38)
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction (2021) (38)
First‐in‐Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure (2013) (38)
Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials (2020) (38)
An NPPB Promoter Polymorphism Associated With Elevated N‐Terminal pro–B‐Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality (2017) (38)
High‐dose influenza vaccine to reduce clinical outcomes in high‐risk cardiovascular patients: Rationale and design of the INVESTED trial☆☆ (2018) (37)
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impa (2018) (37)
Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk. (2008) (36)
Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure (2013) (36)
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia (2017) (36)
Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study (2018) (35)
Guideline‐Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure (2018) (33)
Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure. (2018) (32)
Influenza vaccination: a one-shot deal to reduce cardiovascular events (2016) (29)
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. (2020) (28)
Conduct of Clinical Trials in the Era of COVID-19 (2020) (28)
2022 American College of Cardiology/American Heart Association/Heart Failure Society of America Guideline for the Management of Heart Failure: Executive Summary (2022) (27)
Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction (2018) (24)
In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. (2021) (24)
Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study (2013) (24)
Pharmacy Students' Retention of Knowledge and Skills Following Training in Automated External Defibrillator Use (2010) (21)
Association of Influenza Vaccination With Cardiovascular Risk (2022) (21)
Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study (2020) (20)
The Role of Neprilysin Inhibitors in Cardiovascular Disease (2015) (20)
Decreased immune responses to influenza vaccination in patients with heart failure. (2009) (20)
Incidence and Outcomes of Pneumonia in Patients With Heart Failure. (2021) (19)
Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. (2011) (18)
Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. (2020) (17)
Influenza and Heart Failure: A Catchy Comorbid Combination. (2019) (16)
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial (2022) (16)
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial (2021) (16)
Applying the Lessons of Influenza to COVID-19 During a Time of Uncertainty (2020) (16)
Does influenza vaccination influence cardiovascular complications? (2015) (15)
The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS). (2005) (15)
Decreased T‐Cell Responses to Influenza Vaccination in Patients with Heart Failure (2010) (14)
The Sweet Spot: Heart Failure Prevention with SGLT2 inhibitors. (2020) (14)
Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). (2022) (14)
Pharmacogenomics of heart failure: a systematic review. (2016) (12)
Lack of persistence of influenza vaccine antibody titers in patients with heart failure. (2014) (12)
Nonprescription medication use in patients with heart failure: assessment methods, utilization patterns, and discrepancies with medical records. (2013) (12)
Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America (2021) (12)
Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials? (2019) (11)
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial (2021) (11)
Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory. (2022) (11)
Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials (2022) (10)
β2 adrenergic receptor polymorphisms and nocturnal blood pressure dipping status in the Wisconsin Sleep Cohort Study. (2011) (10)
Tolvaptan for Volume Management in Heart Failure (2019) (10)
Abstract 17948: Reduced Loop Diuretic Use in Patients Taking Sacubitril/Valsartan Compared With Enalapril: The Paradigm-HF Study (2016) (9)
Key Articles and Guidelines in the Acute Management and Secondary Prevention of Ischemic Stroke (2013) (9)
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial (2022) (9)
Key Articles and Guidelines in the Primary Prevention of Ischemic Stroke (2013) (9)
β-AR polymorphisms and glycemic and lipid parameters in hypertensive individuals receiving carvedilol or metoprolol. (2012) (9)
The β2 Adrenergic Receptor Gln27Glu Polymorphism Affects Insulin Resistance in Patients With Heart Failure: Possible Modulation by Choice of Beta Blocker (2008) (9)
Influenza vaccination: a ‘shot’ at INVESTing in cardiovascular health (2021) (8)
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. (2021) (8)
High‐Impact Articles Related to the Management of Heart Failure: 2008 Update (2009) (8)
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction (2021) (7)
PARADIGM‐HF Trial: Secondary Analyses Address Unanswered Questions (2018) (7)
Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial (2015) (6)
Incidence , Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated with a Mineralocorticoid Receptor Antagonist (2014) (6)
Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance (2019) (5)
Key Articles Relative to Cardiovascular Pharmacogenomics (2009) (5)
Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan. (2019) (5)
The Use of Herbal Supplements and Alternative Therapies by Patients with Amyotrophic Lateral Sclerosis (ALS) (2005) (5)
Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression (2012) (5)
Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. (2022) (5)
INFLUENCE OF BASELINE AND WORSENING RENAL FUNCTION ON EFFICACY OF SPIRONOLACTONE IN PATIENTS WITH SEVERE HEART FAILURE ENROLLED IN THE RANDOMIZED ALDACTONE EVALUATION (2012) (4)
NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo‐DHF trial (2021) (4)
Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. (2019) (4)
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial (2022) (4)
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial (2022) (3)
Vaccines, Antibodies and Donors: Varying Attitudes and Policies Surrounding COVID-19 and Heart Transplantation (2022) (3)
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER. (2022) (3)
When the VEST Does Not Fit: Representations of Trial Results Deviating From Rigorous Data Interpretation. (2018) (2)
INFLUENCE OF AGE ON EFFICACY AND SAFETY OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (2020) (2)
Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER (2022) (2)
1347The flu vaccine and mortality in hypertension. A Danish nationwide cohort study (2019) (2)
Incidence, Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated With an Aldosterone Antagonist (2012) (2)
Aminoglycosides and other nonsense suppression therapies for the treatment of dystrophinopathy (2009) (2)
Incidence, Predictors, and Outcomes Associated with Hypotensive Episodes among Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (2016) (2)
Influenza vaccine in cardiovascular disease: time to move the needle. (2022) (2)
Association of post‐vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high‐risk cardiovascular disease: the INVESTED trial (2022) (2)
Angiotensin receptor-neprilysin inhibitors in heart failure: a shifting paradigm (2015) (2)
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalemia: Co-001 (2016) (1)
MORTALITY FOLLOWING INITIATION OR DISCONTINUATION OF GUIDELINE DIRECTED MEDICAL THERAPIES IN HOSPITALIZED HEART FAILURE PATIENTS IN THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY (2016) (1)
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. (2022) (1)
Effects of Beta-Blocker Titration on Glucose Homeostasis in Heart Failure. (2009) (1)
Key Articles Related to Complementary and Alternative Medicine in Cardiovascular Disease: Part 2 (2011) (1)
COVID-19 postacute care major organ damage: a systematic review (2022) (1)
High-dose influenza vaccine in older adults. (2016) (1)
Influence of Age on the Efficacy and Safety of Spironolactone in Heart Failure with Preserved Ejection Fraction (2019) (1)
Anti -i nflammatory Drugs, and Cardiovascular Risk (2008) (1)
Influence of Digital Intervention Messaging on Influenza Vaccination Rates Among Adults With Cardiovascular Disease in the United States: Decentralized Randomized Controlled Trial (2022) (1)
Treatment of immune-mediated peripheral neuropathy (2005) (1)
Resistance to antihypertensive treatment and long‐term risk: The Atherosclerosis Risk in Communities study (2021) (1)
Antibody Titers to Influenza Vaccine Wane in Patients with Heart Failure (2009) (1)
CLINICAL PROFILES, MEDICAL THERAPIES, AND OUTCOMES AMONG PATIENTS HOSPITALIZED FOR HF ACROSS THE SPECTRUM OF KIDNEY FUNCTION: THE GWTG-HF REGISTRY (2021) (1)
Key Articles Related to Complementary and Alternative Medicine in Cardiovascular Disease: Part 1 (2010) (1)
Complications in Patients With COVID-19-Reply. (2020) (1)
Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction (2021) (1)
Thyroid dysfunction and incident heart failure phenotypes among older adults: the atherosclerosis risk in communities (aric) study (2020) (1)
Outpatient diuretic intensification as endpoint in HFpEF trials: an analysis from TOPCAT. (2021) (1)
A Retrospective Evaluation of Spironolactone Versus Eplerenone on Potassium Homeostasis and Renal Function (2013) (1)
Effects of β-Blocker Titration on Glucose Homeostasis in Heart Failure (2009) (0)
Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study (2022) (0)
Influence of Diabetes Mellitus on Cardiac Structure and Function and Response to Therapy with LCZ696 in Heart Failure with Preserved Ejection Fraction (2014) (0)
Re: Decreased immune responses to influenza vaccination in patients with heart failure (2010) (0)
Insulin Resistance and Incident Heart Failure (0)
Abstract 16349: Influenza Activity is Associated With Hospitalizations for Heart Failure- Results From the Atherosclerosis Risk in Communities Study (2018) (0)
Abstract 17716: The Risk of Death in Relation to Traditional Markers of Target Organ Damage, Hs-troponin T, And NTproBNP, in Diabetics: The Atherosclerosis Risk in Communities (ARIC) Study (2013) (0)
Determining learning objectives for a Continuing Professional Education using an online needs analysis. (2006) (0)
T‐cell responses to influenza vaccination among patients with heart failure (2008) (0)
Abstract 2038: Impact of Automated External Defibrillator Practical Experience on Second Year Doctor of Pharmacy Students' Performance and Confidence (2007) (0)
Abstract 16996: Cardiac Structure and Function Across the Dysglycemia Spectrum in a Contemporary Bi-Ethnic Elderly Population: The Atherosclerosis Risk in Communities (ARIC) Study (2013) (0)
Epithelial Sodium Channel Genotype Is Associated with Elevated Potassium among Patients with Heart Failure Taking a Mineralocorticoid Receptor Antagonist (2013) (0)
Abstract 153: Estimating Medication Adherence Effects Using Part D Copayment as an Instrumental Variable in Heart Failure Patients (2016) (0)
Abstract 13279: The Association Between Insulin Resistance And Incident Heart Failure In The Aric Study (2012) (0)
B2-AR GENE POLYMORPHISMS AND ASSOCIATIONS WITH DIFFERENTIAL EFFECTS OF CARVEDILOL AND METOPROLOL ON GLYCEMIC AND LIPID VARIABLES IN HYPERTENSION (2011) (0)
Abstract 17027: Generalizability of the US FDA Label for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in the GWTG-HF Registry (2020) (0)
Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors among Medicare Beneficiaries Hospitalized for Heart Failure. (2021) (0)
Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study (2022) (0)
Abstract 14482: Apparent Resistant Hypertension is a Marker of Risk: The Atherosclerosis Risk in Communities (ARIC) Study (2020) (0)
Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. (2023) (0)
Abstract 16608: A Randomized Study of Double-Dose versus Single-Dose Influenza Vaccination in Patients With Heart Failure (2011) (0)
EFFECT OF SACUBITRIL/VALSARTAN VS. ENALAPRIL ON CHANGES IN BACKGROUND MEDICAL THERAPY OVER TIME IN THE PARADIGM-HF TRIAL (2020) (0)
Management of Serum Potassium in Patients with Heart Failure (2020) (0)
RESISTANT HYPERTENSION IS ASSOCIATED WITH AN INCREASED RISK FOR INCIDENT HEART FAILURE IN THE ARIC STUDY (2014) (0)
Impact of needs analyses in determining Continuing Professional Education symposium topic and learning objectives. (2006) (0)
Abstract 19930: Genetically elevated NT-proBNP, Cardiovascular Outcomes and Life Expectancy in Elderly Blacks and Whites (2016) (0)
PII‐1 (2006) (0)
Abstract 12693: Influence of Resting Heart Rate and Changes in Resting Heart Rate on Cardiovascular Outcomes From the Atherosclerosis Risk in Communities Study (2014) (0)
INFLUENCE OF DIABETES ON LEFT VENTRICULAR MASS REGRESSION WITH ALISKIREN, LOSARTAN OR BOTH (2011) (0)
Patient Selection for Mineralocorticoid Receptor Antagonists in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. (2023) (0)
Words Matter: How the Universal Definition of Heart Failure will Influence Research. (2021) (0)
Abstract 17374: Reduced Risk of Hyperkalemia in Heart Failure Patients Treated With an MRA and Sacubitril/Valsartan Compared With Enalapril: The PARADIGM-HF Trial (2016) (0)
Comparison Of Centralized And Traditional Methods Of Heart Failure Hospitalization Endpoint Capture (2022) (0)
MORTALITY, CLINICAL EVENTS AND HEALTHCARE COSTS AFTER A FIRST HOSPITALIZATION FOR HEART FAILURE: INSIGHTS FROM EVOLUTION HF (2023) (0)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (2022) (0)
Response to Letter Regarding Article, “Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study”. (2015) (0)
Abstract P094: Association of Body Mass Index (BMI) with Abnormalities of Cardiac Structure and Function: The Atherosclerosis Risk in Communities (ARIC) Study (2014) (0)
Impact of COVID-19 on Heart Failure Clinical Trials (2023) (0)
Interactions Between Influenza and Heart Failure Hospitalizations-Diagnostic and Pathogenetic Issues-Reply. (2019) (0)
The β2 Adrenergic Receptor Glu27Gln Polymorphism Affects Fasting Glucose, Insulin, and Insulin Resistance after Beta Blocker Titration in Patients with Heart Failure (2007) (0)
The Wisconsin Pharmacy Quality Collaborative - A Statewide Network of Community Pharmacists to Improve Heart Failure Outcomes (2015) (0)
Abstract 16477: Sacubitril/valsartan as a Treatment for Resistant Hypertension in Patients With Heart Failure and Preserved Ejection Fraction (2020) (0)
Abstract 13771: Association of a Renin Genetic Polymorphism With Left Ventricular Mass Regression in Hypertensive Patients Treated With Aliskiren, Losartan, or Both (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Orly Vardeny?

Orly Vardeny is affiliated with the following schools: